See more : TPT Global Tech, Inc. (TPTW) Income Statement Analysis – Financial Results
Complete financial analysis of ChemoCentryx, Inc. (CCXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ChemoCentryx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- WEBTOON Entertainment Inc. Common stock (WBTN) Income Statement Analysis – Financial Results
- Power & Instrumental (Gujarat) Limited (PIGL.NS) Income Statement Analysis – Financial Results
- PureCycle Technologies, Inc. (PCT) Income Statement Analysis – Financial Results
- S.R. Accord Ltd. (SRAC.TA) Income Statement Analysis – Financial Results
- Aptorum Group Limited (APM) Income Statement Analysis – Financial Results
ChemoCentryx, Inc. (CCXI)
About ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.22M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Cost of Revenue | 302.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 31.92M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Gross Profit Ratio | 99.06% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 82.99M | 77.88M | 70.28M | 62.74M | 49.50M | 37.95M | 33.18M | 33.82M | 33.54M | 34.57M | 28.36M | 33.53M | 27.47M | 35.06M |
| General & Administrative | 0.00 | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.85M | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Other Expenses | 302.00K | 0.00 | -176.00K | 0.00 | 0.00 | -500.00K | 0.00 | 0.00 | 27.48M | 29.15M | 0.00 | 0.00 | 0.00 | -536.00K |
| Operating Expenses | 162.14M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Cost & Expenses | 162.45M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Interest Income | 859.00K | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 402.00K | 436.00K | 297.00K | 1.76M |
| Interest Expense | -2.70M | 2.64M | 2.15M | 1.22M | 4.00K | 0.00 | 0.00 | 24.00K | 59.00K | 794.00K | 734.00K | 81.00K | 76.00K | 129.00K |
| Depreciation & Amortization | 3.14M | 797.00K | 1.64M | 512.00K | 418.00K | 348.00K | 477.00K | 543.00K | 576.00K | 592.00K | 754.00K | 660.00K | 713.00K | 707.00K |
| EBITDA | -131.31M | -51.92M | -51.70M | -36.23M | 18.28M | -39.62M | -46.83M | -46.36M | -38.04M | -38.51M | -3.13M | -2.43M | 16.71M | -17.66M |
| EBITDA Ratio | -407.49% | -80.00% | -143.80% | -84.50% | 22.16% | -346.44% | 0.00% | 0.00% | -627.69% | -710.56% | -9.88% | -6.96% | 33.58% | -74.97% |
| Operating Income | -134.45M | -55.18M | -58.30M | -40.27M | 16.49M | -40.72M | -47.69M | -47.40M | -39.12M | -39.63M | -4.30M | -5.96M | 15.70M | -20.13M |
| Operating Income Ratio | -417.24% | -85.03% | -162.17% | -93.92% | 19.99% | -356.10% | 0.00% | 0.00% | -645.46% | -731.32% | -13.58% | -17.09% | 31.55% | -85.46% |
| Total Other Income/Expenses | -1.84M | -179.00K | 2.81M | 2.30M | 1.37M | 757.00K | 384.00K | 470.00K | 442.00K | -261.00K | -316.00K | 2.79M | 221.00K | 1.63M |
| Income Before Tax | -131.76M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.17M | 15.92M | -18.49M |
| Income Before Tax Ratio | -408.87% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -9.09% | 32.00% | -78.52% |
| Income Tax Expense | -2.70M | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 418.00K | -73.00K | 293.00K | -23.00K |
| Net Income | -129.06M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.10M | 15.62M | -18.47M |
| Net Income Ratio | -400.51% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -8.88% | 31.41% | -78.43% |
| EPS | -1.96 | -0.84 | -0.98 | -0.76 | 0.37 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| EPS Diluted | -1.96 | -0.84 | -0.98 | -0.76 | 0.36 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| Weighted Avg Shares Out | 65.69M | 65.69M | 56.90M | 49.81M | 48.41M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
| Weighted Avg Shares Out (Dil) | 65.69M | 65.69M | 56.90M | 49.81M | 49.62M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
Chemocentryx Stock Needs To Hold At Support Or It May Slide Lower
Why Are ChemoCentryx's Shares Trading Higher Today?
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis
2 Growth Stocks That Could Take Off Before the End of the Year
Is the Options Market Predicting a Spike in ChemoCentryx (CCXI) Stock?
ChemoCentryx (CCXI) Up 10.5% Since Last Earnings Report: Can It Continue?
ChemoCentryx to Participate in Two Upcoming Investor Conferences
ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock?
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
Source: https://incomestatements.info
Category: Stock Reports